Overview

This study is for patients who have had surgery to remove brain metastasis and are planned to have stereotactic radiosurgery (SRS) after their brain surgery. It will be optional for patients to have a pre-surgery 18F-Fluciclovine PET/CT scan. The goal of the study is to determine whether a specific imaging agent, known as 18F-Fluciclovine, will help physicians evaluate the extent of surgery and determine if there is any visible tumor above what MRI alone can identify as well as improve the physicians' ability to detect recurring disease. This agent (18F-Fluciclovine) is investigational for the imaging of brain metastases.

Eligibility

Inclusion Criteria:

1. Age ≥ 18 years
2. Performance status, Eastern Cooperative Oncology Group (ECOG) 0-3
3. Radiographic diagnosis of brain metastasis
4. Patient planned for surgical intervention for at least 1 metastasis
5. Patient planned for postoperative SRS

        Male or female patients of reproductive potential need to employ two highly effective and
        acceptable forms of contraception for at least 4 weeks prior to screening and agreement to
        use such a method during study participation and for an additional 1 week after
        post-treatment 18F-Fluciclovine PET/CT. Highly effective and acceptable forms of
        contraception are:
          -  Male condom plus spermicide
          -  Cap plus spermicide
          -  Diaphragm plus spermicide
          -  Copper T
          -  Progesterone T
          -  Levonorgestrel-releasing intrauterine system (e.g., Mirena®)
          -  Implants
          -  Hormone shot or injection
          -  Combined pill
          -  Mini-pill
          -  Patch
        Postmenopausal people on the study (that will not need contraception) is defined as at
        least one of the following:
          -  Amenorrhoeic for 1 year or more following cessation of exogenous hormonal treatments
          -  Luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the
             postmenopausal range for women under 50
          -  Radiation-induced oophorectomy with last menses > 1 year ago
          -  Chemotherapy-induced menopause with >1 year interval since last menses
          -  Surgical sterilization (bilateral oophorectomy or hysterectomy).
        Exclusion Criteria:
          1. Prior anaphylactic reaction to 18F-Fluciclovine
          2. Evidence of leptomeningeal disease
          3. Prior whole-brain radiation therapy
          4. Contraindication to MRI (e.g., due to safety reasons, such as presence of a pacemaker)
          5. Pregnant at the expected time of 18F-fluciclovine administration
          6. Expecting to be breastfeeding at the time of 18F-Fluciclovine and unwilling to stop
             breast-feeding for 24 hours. Temporary cessation of breastfeeding 24 hours after the
             time of imaging is allowed.